That would mark the first time a pharmaceutical derived from botanical cannabis, which is likely to fuel even more interest in the cannabinoid . Consumer interest in cannabidiol has skyrocketed. The US market for hemp-derived CBD was $50 million in 2014. By 2020 it’s expected to hit $736 million.
